$4,800 per signed retainer. About 1,000 cases in the entire litigation. And juries have awarded $555 million in state court.
NEC doesn’t look like any other mass tort. The plaintiff pool is tiny. Every case involves a premature infant who developed a devastating intestinal disease after being fed cow’s milk-based formula. The science is strong. The verdicts are staggering. And the defendants are two of the largest companies in healthcare.
The Verdicts
State courts are where NEC plaintiffs are winning. The numbers are massive relative to the case count.
March 2024. St. Clair County, Illinois. $60 million. Wrongful death of a premature infant fed Enfamil. Mead Johnson lost.
July 2024. St. Louis, Missouri. $495 million. $95 million compensatory. $400 million punitive. An infant fed Similac developed NEC and suffered irreversible neurological damage. Abbott lost.
That’s $555 million across two state court trials. For context, the entire litigation has about 1,000 cases.
The lone defense verdict in state court (October 2024, St. Louis) was vacated in March 2025 after the judge found defense counsel committed bad faith violations. New trial ordered. Lead attorney sanctioned.
The MDL Split
Here’s the unusual dynamic. State courts are delivering massive plaintiff wins. The federal MDL has produced three consecutive defense wins on summary judgment. Different judges, different outcomes.
MDL-3026 sits in the Northern District of Illinois under Judge Rebecca R. Pallmeyer. 779 cases pending. About 1,000 total across all courts.
Three federal bellwethers were dismissed before reaching a jury. Mar v. Abbott: weak plaintiff facts. K.B./Diggs v. Abbott: causation expert excluded on narrow Daubert grounds. Brown v. Abbott: insufficient evidence of safer alternative.
None of these reached a jury. State courts, where juries heard the evidence, awarded $555 million.
The fourth federal bellwether, Inman v. Mead Johnson, is set for July 6, 2026. First Enfamil case in the MDL. A Cook County, Illinois state trial involving four families against Abbott started jury selection on March 4, 2026.
More plaintiffs are filing in state court. The 7th Circuit is reviewing the MDL judge’s rulings that kept cases in federal court. If those rulings are reversed, more cases go to state juries.
The Science
A meta-analysis upheld by the court in May 2025 found 67% increased NEC risk in randomized trials for formula-fed premature infants. In cohort studies, the increase was 226%. In case-control studies, 135% increased odds.
An NIH-funded JAMA study in February 2024 studied 483 extremely preterm infants (born before 29 weeks or under 1,000 grams). Infants fed donor human milk had half the NEC incidence: 4.2% versus 9% for formula-fed.
The biological mechanism is documented. Complex proteins and fats in cow’s milk-based formula overwhelm the premature gut, feed harmful bacteria, and activate inflammatory pathways that destroy intestinal tissue. NEC kills up to 50% of the most premature infants who develop it.
NICUs are increasingly prioritizing donor milk for preterm infants. The medical consensus is shifting.
The FDA, CDC, and NIH issued a joint statement in 2024 saying there’s “no conclusive evidence” that preterm formula causes NEC. The courts haven’t found that statement dispositive. Juries have heard the science and sided with plaintiffs.
The Lead Economics
NEC isn’t on the Whitehardt Hot Tort Report. Not in the top 10. Same reason as mesothelioma: the case volume is too small for mass advertising metrics.
Raw leads cost $550-$650. Signed retainers cost $4,800-$5,400. Among the highest CPAs in active mass tort.
The economics still work. A $5,400 CPA against a $300,000 settlement (mid-tier) is 56:1 MOIC. Against a $500,000 wrongful death case, that’s 93:1. Jury verdicts run $60 million and up.
The high CPA reflects the structurally limited plaintiff pool. NEC affects roughly 7-10% of very low birth weight preterm infants. About 377,000 premature births occur annually in the US, but only a fraction develop NEC from formula exposure with documentation sufficient for litigation.
Who’s Being Sued
Two defendants. Both with deep pockets.
Abbott Laboratories manufactures Similac, Similac Human Milk Fortifier, and Similac Special Care. The products at issue are NICU-only cow’s milk-based formulas for premature infants, not consumer retail formula.
Mead Johnson Nutrition (subsidiary of Reckitt Benckiser) manufactures Enfamil and Enfamil Premature Formula. Same category: hospital-administered preterm formulas and fortifiers.
Some lawsuits also name hospitals as co-defendants for failure to obtain informed consent before formula feeding. Abbott’s CEO stated on the Q2 2025 earnings call that the company would “rather pull the product” than settle. That posture typically precedes negotiation.
The Advertising Playbook
Zero TV. Zero broadcast. NEC runs entirely on digital and content.
The plaintiff pool is too small and too specific for broadcast economics. You don’t find NICU parents watching daytime television spots. You find them searching online for answers about what happened to their baby.
Search and content dominate at 50%. “NEC baby formula lawsuit,” “Similac NEC lawsuit,” and “Enfamil lawsuit” keywords carry high intent. These parents already know something went wrong. They’re looking for confirmation and representation. Every major plaintiff firm has extensive NEC landing pages driving organic acquisition.
Social takes 45%. Meta campaigns targeting NICU parent communities, premature birth support groups, and infant health interest segments. The audience is concentrated and digitally active.
CTV is marginal at 5%. The plaintiff pool is too narrow for household-level targeting to overcome the math. Unlike Roundup or PFAS (massive exposed populations), NEC’s qualifying universe is measured in thousands, not millions.
NEC advertising economics look more like mesothelioma than Roundup. High per-case value. Tiny qualifying pool. High CPAs. Digital-dominant. The firms that win here are building content engines and search presence, not buying media impressions.
Qualification Criteria
NEC has the narrowest qualification criteria in mass tort. Every element must be documented in medical records.
The child must have been born premature, typically before 37 weeks gestational age. Highest risk: under 28 weeks. Low birth weight, particularly under 1,500 grams.
Documented exposure to cow’s milk-based formula or fortifiers (Similac, Enfamil, or NICU variants) during hospital stay or after discharge. Evidence comes from NICU feeding orders, Medication Administration Records, and hospital feeding logs.
Medical diagnosis of necrotizing enterocolitis occurring during or shortly after formula feeding. Hospitalization, surgery (bowel resection), or other medical treatment for NEC complications.
The strongest cases: extremely premature infants under 28 weeks, fed exclusively or primarily cow’s milk formula, with documented NEC diagnosis requiring surgical intervention or resulting in death. Those are the $300,000-$500,000+ cases.
The Play
NEC is a high-value, low-volume tort approaching resolution. Three things to watch.
First, the July 6 bellwether. Inman v. Mead Johnson is the first Enfamil case in the federal MDL. If plaintiffs get past summary judgment and reach a jury, the case dynamic shifts. State courts have shown what juries do with this evidence.
Second, the Cook County trial happening now. Four families against Abbott. State court. Jury trial. If the pattern holds from Missouri and Illinois, another large plaintiff verdict accelerates settlement pressure across the entire litigation.
Third, the settlement math. About 1,000 cases at $300,000-$600,000 average puts a global settlement in the $300-$600 million range. Manageable for Abbott ($40 billion+ revenue) and Reckitt ($14 billion+ revenue). The defendants know the math. Settlement discussions will accelerate after the second wave of bellwethers.
The firms winning NEC aren’t running volume campaigns. They’re building portfolios of documented cases with complete NICU records, formula exposure evidence, and pathology reports. When the settlement grid drops, documentation quality determines payout tier.
References
- In Re: Preterm Infant Nutrition Products Liability Litigation, MDL No. 3026, N.D. Illinois
- NIH-funded JAMA Study: Donor Human Milk vs. Formula and NEC Incidence in Extremely Preterm Infants, February 2024
- Whitehardt Mass Tort Report: Hot Tort Rankings and Lead Economics, Q1 2026
- Reuters. Abbott NEC trial begins in Cook County, Illinois, March 4, 2026
- March of Dimes PeriStats: Premature Birth Rates, 2024